Atrial Fibrillation Clinical Trial
Official title:
Observational Study of the Variation in Health-related Quality of Life and Symptom Burden in Patients Accepted for Catheter Ablation of Atrial Fibrillation in Relation to Biomarkers, Intracardiac Pressures and Echocardiography.
Atrial fibrillation is the most common cardiac arrhythmia. There is a large variation in
symptoms; from almost none to severe but the reason for this is unclear.
The investigators aim to find correlations between symptom burden and intracardiac pressure,
biomarkers and findings with echocardiography in order to find alternative means of
treatment.
It is even intended to study the neurohormonal activation directly after the atrial
fibrillation (AF) initiation in patients eligible for AF radiofrequency ablation.
Atrial fibrillation (AF) is the most common cardiac arrhythmia and more than 1 % of the
population suffers from AF, it is an independent risk factor for ischemic stroke One major
unresolved issue concerning AF is the large variety in symptoms. In some AF is diagnosed
accidentally while in others symptoms are severe and disabling.
It is known that B-type natriuretic peptide (BNP) and atrial natriuretic peptide (ANP) is
stored in nodules in the atrial and ventricular myocytes and is produced in response to
increased 'afterload' and 'preload' to restore and maintain cardiovascular homeostasis.
Vasopressin (AVP), a non-cardiac plasma marker of cardiovascular disease, is released from
the neurohypophysis in response to changes in plasma osmolality and is involved in
osmoregulation and cardiovascular homeostasis. Adrenomodullin originates primarily in
endothelial cells where cellular stress, ischaemia and hypoxia result in an increased
production.
It is well-known that the concentrations of the natriuretic peptides are elevated in
patients with AF and that the plasma concentrations decreased after conversion to sinus
rhythm (SR). Yet their reaction when AF initiates is totally unknown. Moreover the role of
ADM and AVP-hormonal system has not been researched in this category of patients.
Patients scheduled for catheter ablation of AF for the first time will be included; all with
symptoms varying from moderate to severe. Using four health related quality of life forms
the impact of AF on symptoms will be evaluated. Patients will be investigated with
echocardiography, invasive hemodynamics and measurement of the levels of peptide indicators
of heart failure and/or impact on myocardial function. Patients will also be categorized
according to metabolic profile.
The information on this subject is scarce. Hemodynamic data is old and not correlated to
symptoms. Effective and validated means of measuring health related quality of life
including symptoms burden are relatively new tools. The aim is to find correlations between
the impact on health related quality of life and parameters from echocardiographic
measurements, from analysis of biomarkers (peptides) and from analysis of the metabolic
profile.
In order to study the response of these four different neurohormonal systems (represented by
NT-proBNP, MR-proANP, MR-proADM, copeptin) after the initiation of AF, a randomized
interventional clinical sub-study is to be performed where the eligible population of SMURF
main study can be randomized to AF induction or to control if freedom from AF is confirmed
with thumb-ecg during the last 4 days before ablation. 45 patients are to be included to the
sub-study with 2:1 allocation ratio with simple randomization.
If such correlations can be found alternate means for symptoms relief in AF patients can be
identified and further ahead implemented in general health care.
The sub-study can give us a better insight on the AF initiation and the activation of
different neurohormonal systems, an areas which is not well investigated.
;
Observational Model: Case Control, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
Completed |
NCT04571385 -
A Study Evaluating the Efficacy and Safety of AP30663 for Cardioversion in Participants With Atrial Fibrillation (AF)
|
Phase 2 | |
Terminated |
NCT04115735 -
His Bundle Recording From Subclavian Vein
|
||
Completed |
NCT05366803 -
Women's Health Initiative Silent Atrial Fibrillation Recording Study
|
N/A | |
Completed |
NCT02864758 -
Benefit-Risk Of Arterial THrombotic prEvention With Rivaroxaban for Atrial Fibrillation in France
|
||
Recruiting |
NCT05442203 -
Electrocardiogram-based Artificial Intelligence-assisted Detection of Heart Disease
|
N/A | |
Completed |
NCT05599308 -
Evaluation of Blood Pressure Monitor With AFib Screening Feature
|
N/A | |
Completed |
NCT03790917 -
Assessment of Adherence to New Oral anTicoagulants in Atrial Fibrillation patiEnts Within the Outpatient registrY
|
||
Enrolling by invitation |
NCT05890274 -
Atrial Fibrillation (AF) and Electrocardiogram (EKG) Interpretation Project ECHO
|
N/A | |
Recruiting |
NCT05316870 -
Construction and Effect Evaluation of Anticoagulation Management Model in Atrial Fibrillation
|
N/A | |
Recruiting |
NCT05266144 -
Atrial Fibrillation Patients Treated With Catheter Ablation
|
||
Not yet recruiting |
NCT06023784 -
The Impact of LBBAP vs RVP on the Incidence of New-onset Atrial Fibrillation in Patients With Atrioventricular Block
|
N/A | |
Recruiting |
NCT05572814 -
Transform: Teaching, Technology, and Teams
|
N/A | |
Recruiting |
NCT04092985 -
Smart Watch iECG for the Detection of Cardiac Arrhythmias
|
||
Completed |
NCT04087122 -
Evaluate the Efficiency Impact of Conducting Active Temperature Management During Cardiac Cryoablation Procedures
|
N/A | |
Completed |
NCT06283654 -
Relieving the Emergency Department by Using a 1-lead ECG Device for Atrial Fibrillation Patients After Pulmonary Vein Isolation
|
||
Recruiting |
NCT05416086 -
iCLAS™ Cryoablation System Post-Market Clinical Follow-up (PMCF) Study
|
N/A | |
Completed |
NCT05067114 -
Solutions for Atrial Fibrillation Edvocacy (SAFE)
|
||
Completed |
NCT04546763 -
Study Watch AF Detection At Home
|
||
Completed |
NCT03761394 -
Pulsewatch: Smartwatch Monitoring for Atrial Fibrillation After Stroke
|
N/A |